(Q38184790)

30 August 2017

Fibroblast-mediated pathways in cardiac hypertrophy (English)

1 reference

30 August 2017

Katsuhito Fujiu

1

1 reference

PubMed ID

24492068

30 August 2017

Ryozo Nagai

series ordinal

2

1 reference

30 August 2017

31 January 2014

1 reference

Journal of Molecular and Cellular Cardiology

30 August 2017

1 reference

30 August 2017

70

1 reference

30 August 2017

64-73

1 reference

Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Strategies of conditional gene expression in myocardium: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Origin of cardiac fibroblasts and the role of periostin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Importance of myocyte-nonmyocyte interactions in cardiac development and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Coronary microvascular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Fibroblast growth factor 2 isoforms and cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Fibroblast growth factor-2 mediates pressure-induced hypertrophic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Mechanisms of regulated unconventional protein secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

FGF-16 is required for embryonic heart development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Notch signalling: a simple pathway becomes complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The multifaceted role of Notch in cardiac development and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Notch signaling in cardiac development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Functional role of Notch signaling in the developing and postnatal heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Adult cardiac stem cells are multipotent and support myocardial regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Control of the adaptive response of the heart to stress via the Notch1 receptor pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Activation of Notch-mediated protective signaling in the myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Distinct roles for cell-autonomous Notch signaling in cardiomyocytes of the embryonic and adult heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

A dynamic notch injury response activates epicardium and contributes to fibrosis repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Connective tissue growth factor induces cardiac hypertrophy through Akt signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

ECM remodeling in hypertensive heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Matricellular proteins in the heart: possible role during stress and remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

A thrombospondin-dependent pathway for a protective ER stress response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

New insights into the mechanism of Wnt signaling pathway activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt-1 regulation of connexin43 in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt1/βcatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Premature myocardial infarction is associated with low serum levels of Wnt-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt3a induces myofibroblast differentiation by upregulating TGF-β signaling through SMAD2 in a β-catenin-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Cardiac hypertrophy and the Wnt/Frizzled pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Increased expression of a homologue of drosophila tissue polarity gene "frizzled" in left ventricular hypertrophy in the rat, as identified by subtractive hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Cardiac-specific haploinsufficiency of beta-catenin attenuates cardiac hypertrophy but enhances fetal gene expression in response to aortic constriction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Beta-catenin downregulation is required for adaptive cardiac remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

A Hippo in the ointment: MST signalling beyond the fly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Hippo pathway effector Yap promotes cardiac regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Lats2 is a negative regulator of myocyte size in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Isolation and characterization of a calcium-binding protein derived from mRNA termed p9Ka, pEL-98, 18A2, or 42A by the newly synthesized vasorelaxant W-66 affinity chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

S100A4, a mediator of metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Evidence that fibroblasts derive from epithelium during tissue fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Regression of cellular hypertrophy after left ventricular assist device support

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Angiogenesis in skeletal and cardiac muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Cytochrome c oxidase is essential for copper-induced regression of cardiomyocyte hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Copper regulation of hypoxia-inducible factor-1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Influence of prolonged ventricular assistance on myocardial histopathology in intact heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Improved Left Ventricular Function After Chronic Left Ventricular Unloading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Regression of myocardial hypertrophy after aortic valve replacement: faster in women?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Prevalence and clinical significance of left atrial remodeling in competitive athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Clinical significance of abnormal electrocardiographic patterns in trained athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2014.01.013

10.1016/J.YJMCC.2014.01.013

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24492068